Comparative Pharmacology
Head-to-head clinical analysis: CLARAVIS versus TARGRETIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLARAVIS versus TARGRETIN.
CLARAVIS vs TARGRETIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Isotretinoin, a retinoid, reduces sebum production, inhibits sebaceous gland activity, and normalizes follicular keratinization. It also exhibits anti-inflammatory effects.
Selective retinoid X receptor (RXR) agonist that modulates gene expression involved in cell differentiation, proliferation, and apoptosis.
Oral: 30 mg once daily after a meal for 12 weeks; administration with high-fat meal increases absorption.
300 mg/m2 orally once daily.
None Documented
None Documented
Terminal half-life: 19-24 hours in adults; prolonged in renal impairment (up to 50 hours in ESRD).
Terminal elimination half-life is approximately 7 hours (range 3–10 hours) for the parent drug. The active metabolite (bexarotene glucuronide) has a half-life of about 9 hours. Clinically, steady state is reached within 3–5 days.
Renal: 90% as unchanged drug; fecal: 5%; biliary: <1%.
Primarily metabolized in the liver via CYP3A4; elimination is mainly through hepatobiliary excretion into feces. Renal excretion is minimal (<3% as unchanged drug).
Category C
Category C
Retinoid
Retinoid